The hope for effective means has already driven the shares of some small pharmaceutical companies to unimagined heights during the corona crisis. But none shows a more phenomenal price increase of more than 40,000% than Relief Therapeutics. This is due, on the one hand, to the fact that it was still valued at just CHF 2 million on the stock exchange at the beginning of the year, and on the other hand, because of the prospect of a drug against Covid-19.
Since the company announced the first results of its active ingredient Aviptadil (RLF-100) last week, the shares have taken off. In an interview with “Finanz und Wirtschaft”, Chairman of the Board of Directors Raghuram Selvaraju is confident: “We hope that Aviptadil delivers better results than Remdesivir.” Gilead’s drug is the first and so far only in a scientific study to have a positive effect on disease progression and has received emergency approval.
Please log in to read this article in full.
–
